The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Hesse named president, CEO of CTCA Philadelphia center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NANCY HESSE was named president and CEO of the Cancer Treatment Centers of America Eastern Regional Medical Center (Eastern) in Philadelphia.

Hesse has served as interim president and CEO since February 2016, and before that as chief nursing executive for CTCA and chief nursing officer at Eastern.

Hesse joined CTCA in 2014 after a long tenure at Abington Memorial Hospital. She began her career as a staff nurse in the Emergency Trauma Center and advanced to become the Director of Emergency Trauma and then Chief Nursing Officer for Abington – Lansdale Hospital.

CTCA is a national network of five cancer hospitals.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account